Availability Increased With Approval of Naloxone as OTC Medication
By Elana Gotkine HealthDay Reporter
FRIDAY, Aug. 2, 2024 -- Recently, there was an increase in availability of naloxone after it was approved to be sold as an over-the-counter (OTC) medication, according to a study published online July 26 in JAMA Health Forum.
Grace T. Marley, Pharm.D., from the UNC Eshelman School of Pharmacy in Chapel Hill, North Carolina, and colleagues examined whether the accessibility and cost of naloxone at North Carolina community pharmacies changed after OTC naloxone became available. Data were collected from shoppers at 192 pharmacies in a longitudinal survey study. Data were collected from March to April 2023 (before OTC naloxone could be sold at pharmacies) and from November 2023 to January 2024 (after naloxone was sold at pharmacies).
The researchers found that from before to after naloxone availability at pharmacies, there was an increase in same-day naloxone availability from 42.2 to 57.8 percent. The mean quoted out-of-pocket cost decreased from $90.93 to $62.67 pre- to post-OTC availability. In both the pre- and post-OTC phases, mean costs were significantly higher at independent pharmacies than chain pharmacies ($109.47 versus $86.40 and $77.59 versus $57.74, respectively). In the pre-OTC phase, there was no difference seen in out-of-pocket costs by urbanicity, while mean costs were significantly higher at suburban and rural versus urban pharmacies in the post-OTC phase ($88.67 and $65.43, respectively, versus $53.58).
"This study found elevated out-of-pocket costs for naloxone at independent pharmacies compared with chain pharmacies and in rural and suburban pharmacies compared with urban pharmacies," the authors write. "Overall, future work should evaluate OTC naloxone pricing strategies at pharmacies and evaluate methods to increase its same-day availability."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted August 2024
Read this next
Program Can Prevent Adverse Childhood Experiences in Indigenous Children
TUESDAY, Aug. 13, 2024 -- A seven-session program that teaches skills to prevent adverse childhood experiences (ACEs) in a largely indigenous population shows promise for...
Tailored Texts May Increase Physical Activity in Patients With CVD
TUESDAY, Aug. 13, 2024 -- Tailored text messages may encourage an increase in physical activity in patients undergoing cardiac rehabilitation, according to a study recently...
Routine Clinical Laboratory Measures Are Not Biomarkers of Long COVID
TUESDAY, Aug. 13, 2024 -- Routine clinical laboratory values do not serve as biomarkers for postacute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.